FLT3-IN-19

• CAT Number: I041153
• CAS Number: 2237234-48-7
• Molecular Formula: C22H26N8O
• Molecular Weight: 418.49
• Purity: ≥95%
• Synonyms: 4-[(2-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino]-N-(4-piperazin-1-ylphenyl)-1H-pyrazole-5-carboxamide
• InChI: InChI=1S/C22H26N8O/c1-14-25-18-4-2-3-17(18)21(26-14)28-19-13-24-29-20(19)22(31)27-15-5-7-16(8-6-15)30-11-9-23-10-12-30/h5-8,13,23H,2-4,9-12H2,1H3,(H,24,29)(H,27,31)(H,25,26,28)
• InChIKey: DXUDRTZDTCQOLU-UHFFFAOYSA-N
• SMILES: CC1=NC2=C(CCC2)C(=N1)NC3=C(NN=C3)C(=O)NC4=CC=C(C=C4)N5CCNCC5

FLT3-IN-19（Cat No.:I041153）is a selective small molecule inhibitor that targets FLT3 (Fms-like tyrosine kinase 3), a receptor tyrosine kinase involved in hematopoiesis and the pathogenesis of certain cancers, particularly acute myeloid leukemia (AML). FLT3 mutations, such as FLT3-ITD (internal tandem duplication), are associated with poor prognosis in AML patients. By inhibiting FLT3 kinase activity, FLT3-IN-19 blocks downstream signaling pathways crucial for leukemia cell survival, proliferation, and drug resistance. This compound is being investigated as a potential therapeutic agent in AML and other FLT3-driven malignancies, offering targeted treatment options for patients with resistant forms of the disease.